首页> 美国卫生研究院文献>Contemporary Clinical Trials Communications >The MEDGICarb-Study: Design of a multi-center randomized controlled trial to determine the differential health-promoting effects of low- and high-glycemic index Mediterranean-style eating patterns
【2h】

The MEDGICarb-Study: Design of a multi-center randomized controlled trial to determine the differential health-promoting effects of low- and high-glycemic index Mediterranean-style eating patterns

机译:Medgicarb-Studio:设计多中心随机对照试验以确定低血糖指数地中海风格饮食模式的差分健康促进效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adults with central adiposity and other features of the metabolic syndrome have a markedly elevated risk of developing type 2 diabetes (T2D) and cardiovascular disease (CVD). A Mediterranean-style healthy eating pattern (MED-HEP) and consumption of foods with a lower glycemic index (GI) are potential dietary approaches to curb the T2D and CVD epidemic. However, experimental evidence of the effectiveness of MED-HEP and of the contribution of GI towards improving indices of glucose homeostasis, especially among non-diabetic people, are lacking. Therefore, we developed the MedGI-Carb trial, a multi-center (Italy, Sweden, and United States) intervention in adults with at least two components of the metabolic syndrome (elevated waist circumference + one other component) that aims to improve markers of glucose homeostasis through dietary modification. All participants were randomized to consume an isocaloric high- or low-GI MED-HEP for 12 weeks. We hypothesized that indexes of insulinemia (primary outcome: postprandial insulin and glucose after standardized breakfast and lunch; secondary outcomes: fasting plasma glucose and insulin, HbA1c, 24-h continuous glucose monitoring) would be improved more with the low-GI versus the high-GI MED-HEP. Additionally, we hypothesized that consumption of a MED-HEP would improve other markers of cardiometabolic health and well-being (fasting blood pressure, fasting lipid profile, sleep quality, satiety, global metabolic alterations in the plasma metabolome, changes in the gut microbiota, subjective health and well-being), with no difference between groups. Collectively, the design of MEDGI-Carb allows several different research questions to be explored. TRIAL REGISTRATION: ClinicalTrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT03410719","term_id":"NCT03410719"}}NCT03410719.
机译:具有中央肥胖性和代谢综合征的其他特征的成年人具有显着提高的发育2型糖尿病(T2D)和心血管疾病(CVD)的风险。地中海风格的健康饮食模式(MED-HEP)和血糖指数(GI)的食物消耗是抑制T2D和CVD流行病的潜在饮食方法。然而,缺乏医疗医疗医疗和GI措施的实验证据和GI改善葡萄糖稳态索引的贡献,特别是在非糖尿病人中。因此,我们开发了Medgi-Carb审判,一个多中心(意大利,瑞典和美国)在成年人中进行干预,所述成年人至少有两种代谢综合征(腰围+一个其他组成部分),旨在改善标志物通过膳食改性葡萄糖稳态。所有参与者随机消耗异常的高或低GI MED-HEP 12周。我们假设胰岛素血症的指标(主要结果:标准化早餐和午餐后的后胰岛素和葡萄糖;二次结果:禁食血浆葡萄糖和胰岛素,HBA1c,24-H连续葡萄糖监测)将更多地利用低GI与高-gi med-hep。此外,我们假设Med-hep的消费会改善心细素健康和幸福的其他标志(禁食血压,禁食脂质曲线,睡眠质量,饱腹,血浆代谢中的全球代谢改变,肠道微生物症的变化,主观健康和福祉),群体之间没有区别。集体,Medgi-Carb的设计允许探索几种不同的研究问题。试验注册:ClinicalTrials.gov标识符:{“类型”:“临床试验”,“attrs”:{“text”:“nct03410719”,“term_id”:“nct03410719”}} nct03410719。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号